| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $81,480,546 | 27 | 100 |
| Kelley Shannon T | General Counsel | 0 | $0 | 3 | $841,612 | $-841,612 |
| Soergel David | Chief Medical Officer | 0 | $0 | 2 | $951,981 | $-951,981 |
| Huntsman Carole | Chief Commercial Officer | 0 | $0 | 3 | $1.71M | $-1.71M |
| Dier Mardi | EVP and CFO | 0 | $0 | 3 | $3.77M | $-3.77M |
| Levy Richard S | director | 0 | $0 | 2 | $7.36M | $-7.36M |
| BATE KENNETH | director | 0 | $0 | 1 | $8.03M | $-8.03M |
| Sibold William John | President and CEO | 0 | $0 | 6 | $10.48M | $-10.48M |
| Taub Rebecca | director | 0 | $0 | 5 | $21.68M | $-21.68M |
| FRIEDMAN PAUL A | director | 0 | $0 | 2 | $26.66M | $-26.66M |
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup …
Over the last 12 months, insiders at Madrigal Pharmaceuticals, Inc. have bought $0 and sold $81.48M worth of Madrigal Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Madrigal Pharmaceuticals, Inc. have bought $69.84M and sold $83.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 59,901 shares for transaction amount of $23.07M was made by BAKER BROS. ADVISORS LP (director) on 2025‑08‑20.
| 2026-09-11 | Sale | Sibold William John | President and CEO | 5,221 0.0229% | $542.39 | $2.83M | -10.77% | |
| 2026-09-09 | Sale | Sibold William John | President and CEO | 6,362 0.027% | $535.59 | $3.41M | -10.78% | |
| 2026-08-17 | Sale | Kelley Shannon T | General Counsel | 664 0.0022% | $514.97 | $341,940 | -2.42% | |
| 2026-07-20 | Sale | Sibold William John | President and CEO | 2,500 0.0107% | $547.30 | $1.37M | -4.20% | |
| 2026-06-01 | Sale | Soergel David | Chief Medical Officer | 1,042 0.0045% | $495.74 | $516,561 | +6.67% | |
| 2026-05-22 | Sale | Levy Richard S | director | 5,682 0.0247% | $515.44 | $2.93M | -0.74% | |
| 2026-05-18 | Sale | Soergel David | Chief Medical Officer | 844 0.0036% | $515.90 | $435,420 | -1.68% | |
| 2026-03-06 | Sale | Taub Rebecca | director | 491 0.0022% | $431.94 | $212,083 | +18.78% | |
| 2026-03-06 | Sale | Sibold William John | President and CEO | 1,663 0.0073% | $431.94 | $718,316 | +18.78% | |
| 2026-03-06 | Sale | Huntsman Carole | Chief Commercial Officer | 419 0.0018% | $431.94 | $180,983 | +18.78% | |
| 2026-03-06 | Sale | Dier Mardi | EVP and CFO | 1,982 0.0087% | $430.87 | $853,993 | +18.78% | |
| 2026-03-06 | Sale | Kelley Shannon T | General Counsel | 360 0.0016% | $431.94 | $155,498 | +18.78% | |
| 2026-03-02 | Sale | Dier Mardi | EVP and CFO | 1,183 0.0052% | $427.21 | $505,389 | +17.93% | |
| 2026-01-26 | Sale | Taub Rebecca | director | 647 0.0028% | $492.42 | $318,596 | +2.53% | |
| 2026-01-26 | Sale | Sibold William John | President and CEO | 1,577 0.0068% | $492.42 | $776,546 | +2.53% | |
| 2026-01-26 | Sale | Huntsman Carole | Chief Commercial Officer | 910 0.004% | $493.78 | $449,339 | +2.53% | |
| 2026-01-20 | Sale | Taub Rebecca | director | 2,238 0.0096% | $490.77 | $1.1M | +1.07% | |
| 2026-01-20 | Sale | Kelley Shannon T | General Counsel | 692 0.003% | $497.36 | $344,173 | +1.07% | |
| 2026-01-09 | Sale | Taub Rebecca | director | 18,650 0.0855% | $522.76 | $9.75M | -0.78% | |
| 2026-01-09 | Sale | FRIEDMAN PAUL A | director | 24,800 0.1137% | $522.71 | $12.96M | -0.78% |
| FRIEDMAN PAUL A | director | 187164 0.8101% | $74.18M | 2 | 13 | <0.0001% |
| Levy Richard S | director | 22015 0.0953% | $8.72M | 3 | 6 | +602.61% |
| Bahcall Safi R | President and CEO | 2053135 8.8865% | $813.7M | 12 | 0 | +16.52% |
| BAKER BROS. ADVISORS LP | director | 1947968 8.4313% | $772.02M | 11 | 0 | +28.93% |
| Gollust Keith R | director | 1539169 6.6619% | $610M | 13 | 7 | +9.47% |
| WILSON ROBERT N | director | 754118 3.264% | $298.87M | 5 | 0 | <0.0001% |
| Chen Lan Bo | 620035 2.6837% | $245.73M | 1 | 0 | +32.54% | |
| Chen Lin Huey | 10 percent owner | 620035 2.6837% | $245.73M | 1 | 0 | +32.54% |
| CRAVES FRED B | director | 350076 1.5152% | $138.74M | 1 | 10 | <0.0001% |
| Kovner Bruce | 340970 1.4758% | $135.13M | 51 | 21 | +19.69% | |
| REARDON WILLIAM S | director | 36561 0.1582% | $14.49M | 1 | 0 | +11.11% |
| Vukovic Vojo | SVP, Chief Medical Officer | 35249 0.1526% | $13.97M | 6 | 2 | +36.93% |
| Jacobson Eric W | Sr. VP, Research and CMO | 25300 0.1095% | $10.03M | 1 | 0 | |
| Koya Keizo | Sr. VP, Drug Development | 12999 0.0563% | $5.15M | 1 | 4 | +26.49% |
| Williams Martin D | Sr. VP, Business Dev., CBO | 200 0.0009% | $79,264.00 | 1 | 0 |
$159,914,414 | 243 | 18.52% | $8.86B | |
Madrigal Pharmaceuticals, Inc. (MDGL) | $273,531,368 | 93 | 38.24% | $9.16B |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$98,300,471 | 40 | 0.27% | $14.91B |
| Increased Positions | 232 | +62.7% | 2M | +8.77% |
| Decreased Positions | 158 | -42.7% | 2M | -8.22% |
| New Positions | 90 | New | 321,386 | New |
| Sold Out Positions | 42 | Sold Out | 304,618 | Sold Out |
| Total Postitions | 444 | +20% | 24M | +0.55% |
| Baker Bros. Advisors Lp | $1.27M | 9.31% | 2.14M | +165,683 | +8.38% | 2025-09-30 |
| Rtw Investments, Lp | $1.18M | 8.67% | 1.99M | 0 | 0% | 2025-09-30 |
| Paulson & Co. Inc. | $1.13M | 8.29% | 1.91M | -182,000 | -8.71% | 2025-09-30 |
| Janus Henderson Group Plc | $1.09M | 8.01% | 1.84M | -349,063 | -15.93% | 2025-09-30 |
| Avoro Capital Advisors Llc | $1.09M | 7.97% | 1.83M | -42,000 | -2.24% | 2025-09-30 |
| Vanguard Group Inc | $1.08M | 7.88% | 1.81M | -65,227 | -3.48% | 2025-09-30 |
| Blackrock, Inc. | $926,266.00 | 6.78% | 1.56M | +120,988 | +8.41% | 2025-09-30 |
| State Street Corp | $390,824.00 | 2.86% | 658,097 | -32,618 | -4.72% | 2025-09-30 |
| Geode Capital Management, Llc | $265,004.00 | 1.94% | 446,233 | +31,841 | +7.68% | 2025-09-30 |
| William Blair Investment Management, Llc | $244,557.00 | 1.79% | 411,802 | +61,513 | +17.56% | 2025-09-30 |